Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01492036 · ClinicalTrials.gov registry record

Long-Term Follow-Up of Recipient of Gene Transfer Research

A clinical trial of Cancer and Retroviridae Infections, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
130
Enrollment target
1
Study location

NCT01492036 is a study of Cancer and Retroviridae Infections that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 130 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01492036, a study of Cancer and Retroviridae Infections, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
130 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to collect information about the long-term safety of gene transfer therapy. This study is also designed to create a database of medical information about patients who have received gene transfer therapy, in order for researchers to track and review the long-term safety and any effects (good or bad) of gene transfer therapy.

Interventions

  • OTHER Blood Tests
  • BEHAVIORAL Questionnaires

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2011-12-09
Est. Completion 2027-12-31

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT01492036

The ClinicalTrials.gov registry entry for NCT01492036 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Blood Tests is the first listed.

NCT01492036 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01492036 about?

NCT01492036 is a clinical study titled "Long-Term Follow-Up of Recipient of Gene Transfer Research". The goal of this clinical research study is to collect information about the long-term safety of gene transfer therapy. This study is also designed to create a database of medical information about patients who have received gene transfer therapy, in order for researchers to track and review the lon...

What is the current status of trial NCT01492036?

This trial is currently recruiting. The enrollment target is 130 participants. The study started on 2011-12-09. Estimated completion is 2027-12-31.

What conditions does trial NCT01492036 study?

This clinical trial studies the following conditions: Cancer, Retroviridae Infections.

What interventions are being tested in trial NCT01492036?

The interventions under investigation include: Blood Tests (OTHER), Questionnaires (BEHAVIORAL).

Who is sponsoring clinical trial NCT01492036?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01492036 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.